Text to be removed highlighted in red.
230:1 Conditions of Genetic Testing. RSA 141-H:2, IV is repealed and reenacted to read as follows:
IV.(a) Nothing in this section shall limit genetic testing or genetic analysis used for diagnosis and treatment of a consenting patient by a clinical laboratory that has received a specimen referral from the individual patient's treating physician, genetic counselor, or another clinical laboratory.
(b) This section allows for the disclosure of genetic testing or genetic analysis to entities participating in the clinical care of the patient.
(c) Nothing in this section shall be construed to waive the requirement that the treating physician obtain specific informed patient consent in accordance with the provisions of this section for clinical research.
230:2 Effective Date. This act shall take effect 60 days after its passage.
Approved: August 04, 2023
Effective Date: October 03, 2023
Text to be added highlighted in green.
230:1 Conditions of Genetic Testing. RSA 141-H:2, IV is repealed and reenacted to read as follows:
IV.(a) Nothing in this section shall limit genetic testing or genetic analysis used for diagnosis and treatment of a consenting patient by a clinical laboratory that has received a specimen referral from the individual patient's treating physician, genetic counselor, or another clinical laboratory.
(b) This section allows for the disclosure of genetic testing or genetic analysis to entities participating in the clinical care of the patient.
(c) Nothing in this section shall be construed to waive the requirement that the treating physician obtain specific informed patient consent in accordance with the provisions of this section for clinical research.
230:2 Effective Date. This act shall take effect 60 days after its passage.
Approved: August 04, 2023
Effective Date: October 03, 2023